NCT03262168

Brief Summary

This study will evaluate if the introduction of a supported exercise programme can improve physical and psychological well-being for adults with congenital heart disease.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 7, 2017

Completed
2 months until next milestone

Study Start

First participant enrolled

June 2, 2017

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 25, 2017

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 21, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 21, 2018

Completed
Last Updated

July 31, 2019

Status Verified

July 1, 2019

Enrollment Period

1.6 years

First QC Date

April 7, 2017

Last Update Submit

July 30, 2019

Conditions

Keywords

ExercisePhysical Activity

Outcome Measures

Primary Outcomes (2)

  • Attendance rate

    Determine the feasibility of introducing a supported exercise programme in to clinical practice. This will be measured through attendance to the programme and interaction with the online resource.

    12 weeks (for each phase)

  • Attrition rate

    Determine the feasibility of introducing a supported exercise programme by assessing attrition rate throughout the study period.

    12 weeks (for each phase)

Secondary Outcomes (9)

  • Change in six minute walk test (6MWT)

    12 weeks (for each phase)

  • Change in Sniff Nasal Inspiratory Pressure (SNIP)

    12 weeks (for each phase)

  • Change in Grip Strength

    12 weeks (for each phase)

  • Is there an improvement in level of psychological distress

    12 weeks (for each phase)

  • Is there an improvement in level of psychological distress

    12 weeks (for each phase)

  • +4 more secondary outcomes

Study Arms (4)

Study Group One

OTHER

Six Minute Walk Test distance \<450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).

Other: Exercise Programme

Study Group Two

OTHER

Six Minute Walk Test distance \>450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).

Other: Exercise Programme

Study Group One - phase 2

OTHER

Six Minute Walk Test distance \<450metres. Exercise programme including inspiratory muscle trainer for 12 weeks. Contact weekly (via phone or email).

Other: Exercise Programme

Study Group Two - phase 2

OTHER

Six Minute Walk Test distance \>450metres. Exercise programme including walking for 12 weeks. Contact every second week (via phone or email).

Other: Exercise Programme

Interventions

Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.

Study Group OneStudy Group One - phase 2Study Group TwoStudy Group Two - phase 2

Eligibility Criteria

Age16 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Living in Scotland
  • Diagnosis of congenital heart disease
  • Walks less than 450 metres on a 6 minute walk test (Group 1)
  • Walks more than 450 metres on a 6 minute walk test (Group 2)

You may not qualify if:

  • No access to internet or telephone
  • Non English speaking (If the pilot study is successful, we anticipate that materials and programmes could be translated and accessible to non English speakers)
  • Vulnerable adults
  • Severe aortic stenosis or severe left ventricular outflow tract obstruction (LVOTO)
  • Eisenmenger Physiology (ongoing study recruitment with SPVU)
  • Currently prescribed Advanced Pulmonary Vasodilator therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Golden Jubilee National Hospital

Clydebank, G81 4DY, United Kingdom

Location

MeSH Terms

Conditions

Congenital, Hereditary, and Neonatal Diseases and AbnormalitiesHeart DiseasesMotor Activity

Condition Hierarchy (Ancestors)

Cardiovascular DiseasesBehavior

Study Officials

  • Maureen Mason, MSc

    Golden Jubilee Research Institute

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Participants compete a six minute walk test (6MWT). Those who achieve less than 450 metres will be assigned to study group one. Participants who achieve greater than 450 metres on 6MWT will be assigned to study group two.
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 7, 2017

First Posted

August 25, 2017

Study Start

June 2, 2017

Primary Completion

December 21, 2018

Study Completion

December 21, 2018

Last Updated

July 31, 2019

Record last verified: 2019-07

Data Sharing

IPD Sharing
Will not share

No plan to share individual data

Locations